{
    "clinical_study": {
        "@rank": "15063", 
        "acronym": "FMT", 
        "arm_group": [
            {
                "arm_group_label": "Antibiotics in addition to steroids", 
                "arm_group_type": "Experimental", 
                "description": "methylprednisolone-1.5mg/kg up to 60mg daily in two divided doses and in addition the following antibiotics:\nPO Vancomycin 250mg 4 times a day for 3 weeks\nPO Amoxycillin 50mg per Kg divided by 3 (up to 500mg 3 times a day) - for 3 weeks\nPO Metronidazole 5mg per Kg 3 times a day (up to 250mg 3 times a day) - for 3 weeks\nPO Doxycycline 2mg per kg twice a day (up to 100mg  twice a day) - for 3 weeks; OR- For children younger than 8 years: PO Ciprofloxacin 10mg per Kg twice a day (up to 250mg  twice a day) for 3 weeks"
            }, 
            {
                "arm_group_label": "Steroids only", 
                "arm_group_type": "Active Comparator", 
                "description": "methylprednisolone-1.5mg/kg up to 60mg daily in two divided doses"
            }, 
            {
                "arm_group_label": "Open arm", 
                "arm_group_type": "Other", 
                "description": "either the antibiotics and/or FMT (fecal microbiome transplant) may be administered in a non-randomized, uncontrolled open-label arm to any resistant IBD patients"
            }
        ], 
        "brief_summary": {
            "textblock": "the etiology of Inflammatory Bowel Diseases (IBD) is closely associated with the gut\n      microbiome. The results of previous studies on the effectiveness of antibiotics and fecal\n      macrobiota transplantation (FMT) are contradicting.\n\n      Aims:  to evaluate the effectiveness of wide-spectrum antibiotic regimens in acute severe\n      colitis in an addition to standard corticosteroid therapy (UC and isolated \"UC-like\" Crohn's\n      colitis). The secondary aim is to assess the outcome of FMT in those not responding to five\n      days of therapy (in either arm). As an exploratory aim, any IBD patient with a resistant\n      disease to at least two immunosuppressive medications, may be treated with either\n      interventions."
        }, 
        "brief_title": "Manipulating the Microbiome in IBD by Antibiotics and FMT", 
        "completion_date": {
            "#text": "January 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Acute Severe Ulcerative Colitis", 
            "Acute Severe Colitis", 
            "Crohn's Colitis"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Colitis", 
                "Colitis, Ulcerative", 
                "Crohn Disease", 
                "Ulcer"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Children over the age the 2 years and adults of all ages with established\n             diagnosis of UC using standard criteria (26, 27).\n\n          -  Admission for IV steroid therapy\n\n          -  PUCAI of at least 65 points at admission (i.e. severe attack)\n\n          -  PUCAI>45 at enrolment\n\n          -  Ability to swallow antibiotics (pills or syrup)\n\n        Exclusion Criteria:\n\n          -  Disease confined to the rectum (Proctitis).\n\n          -  Antibiotic use in the past 2 weeks.\n\n          -  Any proven infection such as positive stool culture, parasite or C. difficile,\n             urinary tract infection, cellulitis, abscess, pneumonia, line-infections etc.\n\n          -  Fever >38.5, or >38.0c thought to be unrelated to the inflammatory process of active\n             UC.\n\n          -  The probable need for second line medical therapy (infliximab, cyclosporine,\n             tacrolimus) or colectomy within 5 days of enrolment, as judged by the caring\n             physician.\n\n          -  Known allergy to more than one antibiotic regimen from the list below.\n\n          -  Pregnancy."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "2 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 3, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02033408", 
            "org_study_id": "ABCS-FMT-01"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Antibiotics in addition to steroids", 
                    "Open arm"
                ], 
                "description": "PO Vancomycin 250mgX4/d for 3 weeks\nPO Amoxycillin 50mg/Kg divided by 3 (up to 500mgX3/d) - for 3 weeks\nPO Doxycyclin 2mg/kg X2/d (up to 100mgX2/d)  - for 3 weeks; OR- For children younger than 8 years: PO Ciprofloxacin 10mg/Kg X2/2 (up to 250mgX2/d) for 3 weeks\nPatients with known allergy to one of the drugs may be treated with oral Gentamycin (2.5mg/KgX3/d) for 3 weeks instead of the allergenic drug.", 
                "intervention_name": "AB (antibiotics)", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Ciprofloxacin-Ciprodex\u00ae", 
                    "Doxycycline-Doxylin\u00ae", 
                    "Gentamycin-Gentamicin\u00ae", 
                    "Amoxicillin-Amoxyclav\u00ae", 
                    "Vancomycin-Vanco-Teva\u00ae"
                ]
            }, 
            {
                "arm_group_label": [
                    "Steroids only", 
                    "Open arm"
                ], 
                "description": "methylprednisolone (1.5mg/kg up to 60mg daily in two divided doses)\nPO Metronidazole 5mg/Kg X3/d (up to 250mgX3/d) - for 3 weeks", 
                "intervention_name": "CS (corticosteroids) Only", 
                "intervention_type": "Drug", 
                "other_name": "Metronidazole-Flagyl\u00ae"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Amoxicillin", 
                "Anti-Bacterial Agents", 
                "Doxycycline", 
                "Doxycycline hyclate", 
                "Gentamicins", 
                "Vancomycin", 
                "Ciprofloxacin", 
                "Metronidazole", 
                "Antibiotics, Antitubercular", 
                "Methylprednisolone acetate", 
                "Prednisolone acetate", 
                "Methylprednisolone", 
                "Methylprednisolone Hemisuccinate", 
                "Prednisolone", 
                "Prednisolone hemisuccinate", 
                "Prednisolone phosphate"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "IBD: Inflammatory Bowel Diseases", 
            "CD: Crohn's Disease", 
            "UC: Ulcerative Colitis", 
            "ASC: Acute Severe Colitis", 
            "FMT: Fecal Microbiota Transplantation", 
            "PUCAI: Pediatric Ulcerative Colitis Activity Index", 
            "Ciprofloxacin, Doxycycline, Gentamycin, amoxicillin, vancomycin, metronidazole,ciprofloxacin,"
        ], 
        "lastchanged_date": "January 15, 2014", 
        "location": [
            {
                "contact": {
                    "email": "ibd.chen@gmail.com", 
                    "last_name": "chen sarbagili, M.Sc", 
                    "phone": "+972-3-5028878"
                }, 
                "facility": {
                    "address": {
                        "city": "Holon", 
                        "country": "Israel"
                    }, 
                    "name": "Wolfson Medical Center"
                }, 
                "investigator": {
                    "last_name": "Arie Levine, MD", 
                    "role": "Sub-Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "gilif@szmc.org.il", 
                    "last_name": "Gili Focht, MBA", 
                    "phone": "+972-2-5645028"
                }, 
                "facility": {
                    "address": {
                        "city": "Jerusalem", 
                        "country": "Israel", 
                        "zip": "9103102"
                    }, 
                    "name": "Shaare Zedek Medical Center"
                }, 
                "investigator": {
                    "last_name": "Dan Turner, MD PHD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Israel"
        }, 
        "number_of_arms": "3", 
        "official_title": "Manipulating the Microbiome in IBD by Antibiotics and Fecal Microbiota Transplantation (FMT): a Randomized Controlled Trial", 
        "overall_contact": {
            "email": "gilif@szmc.org.il", 
            "last_name": "Gili Focht, MBA", 
            "phone": "+972-2-5645028"
        }, 
        "overall_official": {
            "affiliation": "Shaare Zedek Medical Center", 
            "last_name": "Dan Turner, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Israel: Ministry of Health", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Total PUCAI (Pediatric Ulcerative Colitis Activity Index) score", 
            "safety_issue": "No", 
            "time_frame": "at day 5 after treatment (compared between the two treatment groups)."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02033408"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "defined by PUCAI<10 without the need for second line therapy (anti TNF (Tumor Necrosis Factor), cyclosporine or tacrolimus) or colectomy.", 
                "measure": "Remission rates", 
                "safety_issue": "No", 
                "time_frame": "at days 7, separately at discharge, separately at day 14, and separately at 90 days."
            }, 
            {
                "description": "without the need for second line therapy (anti TNF, cyclosporine or tacrolimus) or colectomy.", 
                "measure": "Number of patients with PUCAI<35 points", 
                "safety_issue": "No", 
                "time_frame": "at day 5"
            }, 
            {
                "measure": "The need for second line therapy or colectomy by discharge", 
                "safety_issue": "No", 
                "time_frame": "by 90 days and at 1 year"
            }, 
            {
                "description": "defined as a course longer than 3 month with an unsuccessful attempt to wean steroids or cumulative steroid treatment months of 4 months, during the year.", 
                "measure": "Rate of steroid", 
                "safety_issue": "No", 
                "time_frame": "dependency at 1 year"
            }, 
            {
                "measure": "Need for subsequent admission", 
                "safety_issue": "No", 
                "time_frame": "by 1 year"
            }, 
            {
                "measure": "Calprotectin levels", 
                "safety_issue": "No", 
                "time_frame": "at 5 and 14 days after treatment."
            }, 
            {
                "measure": "Rate of gastrointestinal carriage of resistant organisms (VRE, ESBL)", 
                "safety_issue": "No", 
                "time_frame": "at days 5 and 14 after treatment."
            }, 
            {
                "measure": "Change in microbiome pattern.", 
                "safety_issue": "No", 
                "time_frame": "3 years from baseline"
            }, 
            {
                "measure": "Rate of C. difficile infection", 
                "safety_issue": "No", 
                "time_frame": "at days 5 and 14 after treatment."
            }
        ], 
        "source": "Shaare Zedek Medical Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Shaare Zedek Medical Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}